Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.08% | 73.38% | 70.20% | -58.48% | -92.56% |
| Total Depreciation and Amortization | -22.31% | 130.41% | 405.84% | 256.85% | 554.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.88% | -84.97% | -88.98% | 1,052.63% | 1,270.28% |
| Change in Net Operating Assets | -135.21% | -123.76% | 95.69% | 378.74% | 289.63% |
| Cash from Operations | 24.34% | 49.95% | 70.12% | 63.41% | 44.45% |
| Capital Expenditure | -- | 107.43% | -1,618.82% | -174.11% | -211.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 101.66% | 115.39% | -1,462.35% | -174.11% | -211.13% |
| Total Debt Issued | -70.00% | -- | -- | -97.24% | -97.88% |
| Total Debt Repaid | -682.48% | -1,895.74% | -2,116.67% | -148.30% | -- |
| Issuance of Common Stock | 165.44% | 23.93% | -69.21% | -73.16% | -77.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.56% | 4.82% | 61.26% | 70.16% | 72.96% |
| Cash from Financing | 146.09% | 16.02% | -71.46% | -80.12% | -82.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.53% | 161.51% | -218.54% | -200.12% | -220.48% |